BridgeMD
New treatment option for HIV Disease Progression
Official title Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)
ClinicalTrials.gov ID: NCT05580666
What this study is testing
What is Azithromycin Oral Tablet?
Azithromycin Oral Tablet is an investigational medicine, being studied as a potential treatment for hiv disease progression.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years
- Documented HIV infection
- CD4 count criteria: i. CD4 count ≤ 100 cells/mm3 within past 4 weeks; or ii. Documented CD4 nadir ≤ 100 cells/mm3 and complete interruption of ART...
- Ability to initiate or re-initiate ART, or switch to an effective ART regimen if failing current therapy, within 4 weeks of enrolment
You likely can't join if
- Contraindications to azithromycin: i. Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic; or ii. Personal or family history...
- Severe illness requiring immediate or continued hospitalization (this will be in the judgment of site investigators)
- Off-label azithromycin prophylaxis or requirement for prolonged (\> 7 days) azithromycin (or macrolide) therapy
The study team makes the final eligibility decision.
Where it's taking place
- Abidjan, Côte d’Ivoire
- Ādama, Ethiopia
- Āsela, Ethiopia
- Jimma, Ethiopia
- Mek'ele, Ethiopia
- Kumasi, Ghana
- Lilongwe, Malawi
- Maputo, Mozambique
- Abuja, Nigeria
- Calabar, Nigeria
- Enugu, Nigeria
- Ibadan, Nigeria
- Jos, Nigeria
- Kano, Nigeria
- Lago, Nigeria
- Sokoto, Nigeria
- Umuahia, Nigeria
- Uyo, Nigeria
- Yenagoa, Nigeria
- Kigali, Rwanda
+ 18 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Abidjan, Côte d’Ivoire; Ādama, Ethiopia; Āsela, Ethiopia; Jimma, Ethiopia; Mek'ele, Ethiopia; Kumasi, Ghana and 32 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.